Vanda Pharmaceuticals (VNDA) News Today $4.36 -0.08 (-1.80%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis CandidateJanuary 16 at 2:19 PM | benzinga.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Barclays PLCBarclays PLC grew its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 128.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 154,297 shares of the biopharmaceutical company's stock after acquiring an additJanuary 16 at 3:03 AM | marketbeat.comHead to Head Contrast: Novo Nordisk A/S (NYSE:NVO) vs. Vanda Pharmaceuticals (NASDAQ:VNDA)January 15 at 2:10 AM | americanbankingnews.comBioxytran (OTCMKTS:BIXT) vs. Vanda Pharmaceuticals (NASDAQ:VNDA) Head to Head SurveyJanuary 13, 2025 | americanbankingnews.comStockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Sunday. They issued a "hold" rating on the stock.January 12, 2025 | marketbeat.comVanda Pharmaceuticals issues letter to FDA on faulty gastroparesis NDA reviewJanuary 9, 2025 | markets.businessinsider.comVanda Pharmaceuticals Inc.: Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA ReviewJanuary 9, 2025 | finanznachrichten.deVanda asserts FDA review of tradipitant was flawedJanuary 8, 2025 | msn.comVanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA ReviewJanuary 8, 2025 | prnewswire.comVanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.comStockNews.com initiated coverage on Vanda Pharmaceuticals in a research note on Saturday. They issued a "hold" rating on the stock.January 4, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Friday. They issued a "hold" rating for the company.December 27, 2024 | marketbeat.comVanda Pharmaceuticals: Promising Pipeline Developments and Market Potential Drive Buy RatingDecember 23, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday.December 23, 2024 | marketbeat.comVanda Pharmaceuticals: Orphan Drug Designation Granted for VGT-1849ADecember 22, 2024 | markets.businessinsider.comVanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer TreatmentDecember 20, 2024 | marketwatch.comVanda Pharma's VGT-1849A Gets Orphan Drug Designation From FDADecember 20, 2024 | markets.businessinsider.comVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia VeraDecember 20, 2024 | prnewswire.comVanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.comStockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday. They issued a "hold" rating for the company.December 11, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Invests $864,000 in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Massachusetts Financial Services Co. MA acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 184,181 shares of the biophNovember 28, 2024 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Stephen Ray Mitchell Sells 5,000 Shares of StockNovember 19, 2024 | insidertrades.comVanda Pharmaceuticals Announces Participation at November 2024 Investor ConferencesNovember 12, 2024 | prnewswire.comBML Capital Management LLC Cuts Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)BML Capital Management LLC decreased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 42.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 228,500 sharesNovember 12, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Vigil Neuroscience Inc (VIGL)November 9, 2024 | markets.businessinsider.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comVanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ...November 7, 2024 | finance.yahoo.comVanda Pharmaceuticals narrows 2024 revenue view to $190M-$210M from $180M-$210MNovember 7, 2024 | markets.businessinsider.comVanda Pharmaceuticals Reports Strong Q3 2024 GrowthNovember 7, 2024 | markets.businessinsider.comVanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comVanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c)November 6, 2024 | tipranks.comVanda Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | prnewswire.comQ3 Earnings Estimate for VNDA Issued By HC WainwrightVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - HC Wainwright issued their Q3 2024 EPS estimates for Vanda Pharmaceuticals in a report released on Thursday, October 31st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings of ($0.16) per shaNovember 4, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDANovember 2, 2024 | prnewswire.comOver 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: AnalystNovember 1, 2024 | benzinga.comResearch Analysts Offer Predictions for VNDA FY2024 EarningsVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Analysts at HC Wainwright issued their FY2024 EPS estimates for shares of Vanda Pharmaceuticals in a report released on Thursday, October 31st. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earningsNovember 1, 2024 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Vanda Pharmaceuticals (VNDA) with Buy RecommendationNovember 1, 2024 | msn.comVanda started at buy by H.C. Wainwright, negative enterprise value citedOctober 31, 2024 | msn.comVanda Pharmaceuticals initiated with a Buy at H.C. WainwrightOctober 31, 2024 | markets.businessinsider.comVanda Pharmaceuticals (VNDA) to Release Earnings on WednesdayVanda Pharmaceuticals (NASDAQ:VNDA) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at HC WainwrightHC Wainwright started coverage on Vanda Pharmaceuticals in a report on Thursday. They set a "buy" rating and a $18.00 price objective for the company.October 31, 2024 | marketbeat.comVanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024October 30, 2024 | prnewswire.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 17.1% in OctoberVanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,980,000 shares, an increase of 17.1% from the September 30th total of 3,400,000 shares. Based on an average daily trading volume, of 596,200 shares, the days-to-cover ratio is currently 6.7 days. Currently, 7.2% of the company's shares are sold short.October 28, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDAOctober 25, 2024 | prnewswire.comBiotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & MoreOctober 18, 2024 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDAOctober 17, 2024 | prnewswire.comCycle Pharmaceuticals reaffirms proposal to acquire Vanda PharmaceuticalsOctober 15, 2024 | finance.yahoo.comVanda Pharma soars as Cycle Pharma reiterates $8/share offer (update)October 14, 2024 | msn.comVanda Shares Climb on Reiterated Cycle Acquisition OfferOctober 14, 2024 | marketwatch.comCycle Pharma Is Said to Stand By $488 Million Offer for VandaOctober 14, 2024 | bloomberg.comVanda Pharmaceuticals rejects Cycle Pharma's second takeover offerOctober 14, 2024 | investing.comVanda Pharmaceuticals Rejects Deal Proposal From Cycle GroupOctober 14, 2024 | marketwatch.com Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Media Mentions By Week VNDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼-0.100.46▲Average Medical News Sentiment VNDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼54▲VNDA Articles Average Week Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ironwood Pharmaceuticals News Today Emergent BioSolutions News Today Codexis News Today Rigel Pharmaceuticals News Today XOMA News Today Verastem News Today Sangamo Therapeutics News Today Lexicon Pharmaceuticals News Today Achieve Life Sciences News Today Regulus Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts